三氮唑类抗真菌药的治疗药物监测研究进展

摘要/Abstract

摘要： 近年来, 真菌感染, 尤其是深部真菌感染严重地威胁到患者的健康和生命, 因此抗真菌药物的研究开发及临床应用日益受到重视。三氮唑类抗真菌药是临床使用最广泛的抗真菌药物, 其临床疗效得到了广泛的肯定。代表药物有氟康唑(Fluconazole)、伊曲康唑(Itraconazole)、伏立康唑(Voriconazole)、泊沙康唑(Posaconazole)等。由于在吸收、代谢和排泄等方面的差异和药物相互作用的影响, 导致许多抗真菌药物血药浓度的个体差异较大。临床实践表明抗真菌药物的血药浓度与其疗效和毒副作用有相关性, 对其进行治疗药物监测可优化治疗效果同时降低毒副作用。本文就近年来国内外三氮唑类抗真菌药物治疗药物监测的研究进展进行综述。

关键词: 治疗药物监测, 伏立康唑, 泊沙康唑, 真菌感染

Abstract: In recent years, the fungal infection, especially the invasive deep fungal infection has becomes a major threat to patients' health and life. Hence, the research and application of antifungal drugs have been paid much more attention than before. The triazole antifungals, such as fluconazole, itraconazole, voriconazole, are some of the most widely used antifungal agents in clinical. Due to the different absorption, metabolism, elimination and interaction with combined medications, the triazole antifungals exhibit remarkable individual difference in blood concentration. Related clinical trials have proved the reasonable relationship between the drug concentration and the clinical effect, at the same time the relationship between drug concentration and toxicity has also been identified. The use of therapeutic drug monitoring (TDM) for these triazoles can optimize their therapeutic effects while reduce possible side effects. This paper summarizes the domestic and international researches on therapeutic drug monitoring of triazole antifungal drugs.

Key words: therapeutic drug monitoring, voriconazole, posaconazole, fungal infections

中图分类号:

R969.1

詹莹, 疏楠, 郭楠, 邵华, 厉伟兰. 三氮唑类抗真菌药的治疗药物监测研究进展[J]. 中国临床药理学与治疗学, 2014, 19(6): 706-711.

ZHAN Ying, SHU Nan, GUO Nan, SHAO Hua, LI Wei-lan. Advances in therapeutic drug monitoring for triazole antifungal agents[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 706-711.

参考文献

[1] Trifilio S. Update on antifungal drug dosing and therapeutic drug monitoring[J]. Curr Fungal Infect Rep, 2011, 5(3): 92-102.
[2] Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications[J]. Antimicrob Agents Chemother, 2009, 53(1): 24-34.
[3] Traunmüller F, Popovic M, Konz KH, et al. Efficacy and safety of current drug therapies for invasive aspergillosis[J]. Pharmacol, 2011, 88(4): 213-224.
[4] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(1): 327-360.
[5] Hagihara M, Kasai H, Umemura T, et al. Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units[J]. J Infect Chemother, 2011, 17(4): 224-230.
[6] Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3, 597 patients[J]. J Clin Oncol, 2003, 21(9): 4615-4626.
[7] Howard SJ, Hope WW. Antifungal therapeutic drug monitoring for invasive aspergillosis[EB/OL]. Aspergillosis: From Diagnosis to Prevention: Springer; 2010, 217-228.
[8] 沈斌. 三唑类抗真菌药代谢性相互作用研究[A]. 2012年浙江省医学会临床药学学术年会暨医院药事管理质控中心、临床药学分会十周年庆典大会论文集[C]. 2012: 327-331.
[9] Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update[J]. J Antimicro chemother, 2008, 61(5): 17-25.
[10]Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities[J]. J Clin Pharmacol, 2006, 46(5): 235-243.
[11]Gómez-López A, Cendejas-Bueno E, Cuesta I, et al. Voriconazole serum levels measured by high- performance liquid chromatography: a monocentric study in treated patients[J]. Med Mycol, 2012, 50(3): 439-445.
[12]Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children[J]. Clin Infect Dis, 2010, 50(4): 27-36.
[13]Dolton MJ, Ray JE, Chen SC-A, et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring[J]. Antimicro Agents Chemother, 2012, 56(2): 4793-4799.
[14]Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients[J]. Antimicro Agents Chemother, 2011, 55(1): 4782-4788.
[15]Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole[J]. J Clin Pharmacol, 2009, 49(5): 196-204.
[16]Hussaini T, Rüping MJGT, Farowski F, et al. Therapeutic drug monitoring of voriconazole and posaconazole[J]. J Hum Pharmacol Drug Thera, 2011, 31(4): 214-225.
[17]Pasqualotto AC, Xavier MO, Andreolla HF, et al. Voriconazole therapeutic drug monitoring: focus on safety[J]. Exp Opin Drug safe, 2010, 9(11): 125-137.
[18]Brüggemann RJM, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole[J]. Therap Drug Monit, 2008, 30(3): 403-411.
[19]Mikulska M, Novelli A, Aversa F, et al. Voriconazole in clinical practice[J]. J Chemother, 2012, 24(12): 311-327.
[20]Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial[J]. Clin Infect Dis, 2012, 55: 1080-1087.
[21]Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity[J]. Antimicro Agents Chemother, 2012, 56(3): 2371-2377.
[22]Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience[J]. Mycoses, 2012, 55(6): 483-492.
[23]Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole[J]. Clin Pharmacokine, 2006, 45(22): 649-63.
[24]Thompson GR, Cadena J, Patterson TF. Overview of antifungal agents[J]. Clin Chest Med, 2009, 30(14): 203-215.
[25]Aperis G, Alivanis P. Posaconazole: A new antifungal weapon[J]. Rev Recent Clin Trials, 2011, 6(3): 204-219.
[26]Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults[J]. Antimicro Agents Chemother, 2009, 53(3): 5224-5229.
[27]Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy[J]. Antimicro Agents Chemother, 2011, 55(24): 1308-1311.
[28]Eiden C, Meniane J, Peyrière H, et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake[J]. Euro J Clin Microbiol Infect Dis, 2012, 31(2): 161-167.
[29]Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis[J]. Clin Infect Dis, 2010, 51(1): 1383-1391.